NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Ensho Therapeutics

Ensho Therapeutics

Private
Morris Plains, New JerseyHealthcare & Life Scienceshttps://www.enshorx.com/

Last Round

Series A

Feb 9, 2026

Total Funding Raised

$27.9M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Ensho Therapeutics is a clinical-stage biopharmaceutical company developing breakthrough oral therapies for patients with inflammatory diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biopharmaceuticalinflammatory bowel diseaseIBDsmall molecule therapyoral drugulcerative colitisCrohn's diseaseintegrin inhibitorclinical trialsdrug developmentbiotechoral biologics alternativepipeline drugpharma R&D

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Ensho Therapeutics Comparables

Compare Ensho Therapeutics with similar companies based on industry and business-model similarity.

Ensho Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Sorriso Therapeutics
82%
Eli Lilly and Company
81%
Protagonist Therapeutics Inc
79%

Ensho Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AFeb 9, 2026
DebtSep 12, 2025
Series AOct 24, 2024
SeedAug 6, 2024

Key People

Founding team and executive leadership

Neena Bitritto-Garg

Founder, President CEO

Founding Team

Danielle Fry

Chief Legal Officer Chief Operating Officer

Executive Team

Ensho Therapeutics Investors

Notable investors and investment history

Ensho Therapeutics investors
InvestorRounds
Avego ManagementSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 18, 2026

    Monthly visitors increased 119% MoM, reaching 2.5K.

  • Feb 21, 2025

    Presenting data on NSHO-101 for inflammatory bowel disease treatment.

Ensho Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Ensho Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Ensho Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersMorris Plains, New Jersey
Employee Range9
Year Founded2024
Last FundingFeb 9, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.